Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ketohexokinase (fructokinase) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Onchocerca volvulus | Get druggable targets OG5_133459 | All targets in OG5_133459 | |
Brugia malayi | hypothetical protein | Get druggable targets OG5_133459 | All targets in OG5_133459 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_133459 | All targets in OG5_133459 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | ribokinase, putative | ketohexokinase (fructokinase) | 298 aa | 307 aa | 21.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | calcium activated potassium channel | 0.0534 | 0.1718 | 0.0074 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0534 | 0.1718 | 0.0037 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0534 | 0.1718 | 0.0037 |
Brugia malayi | Kinase associated domain 1 family protein | 0.053 | 0.1687 | 0.1687 |
Onchocerca volvulus | 0.0312 | 0 | 0.5 | |
Echinococcus multilocularis | serine:threonine protein kinase MARK2 | 0.0534 | 0.1718 | 0.0074 |
Echinococcus multilocularis | maternal embryonic leucine zipper kinase | 0.1071 | 0.589 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0534 | 0.1718 | 0.0037 |
Schistosoma mansoni | serine/threonine kinase | 0.1601 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0534 | 0.1718 | 0.0037 |
Trichomonas vaginalis | CAMK family protein kinase | 0.1601 | 1 | 1 |
Loa Loa (eye worm) | CAMK/CAMKL/MELK protein kinase | 0.1601 | 1 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase MARK2 | 0.0534 | 0.1718 | 0.0074 |
Echinococcus granulosus | maternal embryonic leucine zipper kinase | 0.1071 | 0.589 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0534 | 0.1718 | 0.0037 |
Loa Loa (eye worm) | hypothetical protein | 0.053 | 0.1687 | 0.1687 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 8 nM | Inhibition of human ketohexokinase isoform C expressed in Escherichia coli BL21 (DE3) cells using D-fructose as substrate after 12 to 15 mins by fluorescence polarization assay | ChEMBL. | 24900346 |
IC50 (binding) | = 8 nM | Inhibition of recombinant human hepatic KHKC | ChEMBL. | 22795331 |
IC50 (binding) | = 360 nM | Inhibition of ketokinase isoform C in human HepG2 cells assessed as levels of fructose-1-phosphate preincubated for 30 mins followed by substrate addition measured after 3 hrs by LC-MS analysis | ChEMBL. | 24900346 |
Inhibition (binding) | = 25 % | Inhibition of ABL1 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of ALK4 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of AKT1 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of AMPK A1/B1/G1 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of AURKA at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of CAMK1D at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of CAMK2A at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of CDK1/cyclin B at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of CHEK1 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of CHEK2 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of CSNK1D at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of DAPK3 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of EGFR at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of EPHB1 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of GSK3B at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of INSR at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of IRAK4 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of JAK2 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of MAPK13 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of MST4 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of NEK2 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of NTRK1 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of PAK3 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of PDGFRB at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of PIM2 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of PLK3 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of PRKACA at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of PRKCQ at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of ROCK1 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of RPS6KA3 at 10 uM by FRET assay | ChEMBL. | 22795331 |
Inhibition (binding) | = 25 % | Inhibition of SRC at 10 uM by FRET assay | ChEMBL. | 22795331 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.